More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...
Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia (>40%) that greatly impair patients’ quality of life. Six recent phase 3 ...
Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback